Safi Biotherapeutics, a US biotechnology company developing stem-cell-derived manufactured red blood cells for civilian and military transfusion needs.
Safi Biotherapeutics has secured a $4.7 million non-dilutive award extension through MTEC to advance its stem-cell-derived red blood cell technology and support preparations for its first clinical trial in 2027.

Safi Biotherapeutics, a Cambridge, Massachusetts-based biotechnology company developing manufactured human red blood cells, has received a $4.7 million non-dilutive award extension from the U.S. Department of War’s Defense Health Program, Combat Casualty Care portfolio, through the Medical Technology Enterprise Consortium (MTEC).

The funding will support the company’s remaining Investigational New Drug (IND)-enabling activities ahead of a planned regulatory submission for acute blood loss in 2027. It will also advance the development of a cryopreserved manufactured red blood cell (mRBC) formulation intended for transfusion applications.

Safi Biotherapeutics develops stem-cell-derived human red blood cells as an investigational alternative to conventional donor-supplied blood. Its manufacturing platform is designed to produce red blood cells at a scale suitable for civilian and military transfusion requirements, including emergency trauma care and chronic transfusion needs.

Led by CEO and Co-Founder Doug McConnell, the company is also co-founded by Jon Mogford. Its manufacturing process uses bioreactors to produce red blood cells from stem cells. According to Safi, the process can generate more than one full transfusable unit in a single 10-liter bioreactor.

The company is developing refrigerated, cryopreserved and freeze-dried red blood cell formulations to address different storage and transportation requirements. Its work targets acute transfusion settings, including civilian hospitals and military medical facilities, as well as chronic transfusion indications such as sickle cell disease.

Safi plans to submit an IND application and initiate its first clinical trial in 2027. The latest award will support the preparatory work required before clinical testing.

With the new extension, Safi has received more than $27 million in non-dilutive U.S. government funding to date. The company previously secured $5 million in seed financing in September 2024, led by J2 Ventures.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share